Sandbox Rim: Difference between revisions
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
Line 29: | Line 29: | ||
❑ [[Esophageal rupture|<span style="color:white;">Esophageal rupture</span>]] <br> (suggestive findings: [[vomiting|<span style="color:white;">vomiting</span>]], [[subcutaneous emphysema|<span style="color:white;">subcutaneous emphysema</span>]])</div>}} | ❑ [[Esophageal rupture|<span style="color:white;">Esophageal rupture</span>]] <br> (suggestive findings: [[vomiting|<span style="color:white;">vomiting</span>]], [[subcutaneous emphysema|<span style="color:white;">subcutaneous emphysema</span>]])</div>}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | |!| | | }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | |!| | | }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | A01 | | | | | A01= <div style="float: left; text-align: left; width: 25em; padding:1em;">'''Begin initial treatment:'''<br> ❑ Administer [[aspirin|<span style="color:white;">aspirin</span>]] | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | | | | A01 | | | | | A01= <div style="float: left; text-align: left; width: 25em; padding:1em;">'''Begin initial treatment:'''<br> ❑ Administer [[aspirin|<span style="color:white;">aspirin</span>]] (I-A) | ||
:❑ 162 to 325 mg of non enteric [[aspirin|<span style="color:white;">aspirin</span>]],orally, crushed or chewed, THEN | :❑ 162 to 325 mg of non enteric [[aspirin|<span style="color:white;">aspirin</span>]],orally, crushed or chewed, THEN | ||
:❑ 75 to 325 mg/day | :❑ 75 to 325 mg/day | ||
::''Among patients with either GI intolerance or hypersensitivity against it, administer a loading dose followed by maintenance dose of either clopidogrel (I-B), or prasugrel in PCI patients (I-C), or ticagrelor (I-C)'' | |||
❑ Administer 2-4 L/min [[oxygen|<span style="color:white;">oxygen</span>]] via nasal cannula when saturation <90% | ❑ Administer 2-4 L/min [[oxygen|<span style="color:white;">oxygen</span>]] via nasal cannula when saturation <90% | ||
:❑ Caution in [[COPD|<span style="color:white;">COPD</span>]] patients: maintain an oxygen saturation between 88% and 92% | :❑ Caution in [[COPD|<span style="color:white;">COPD</span>]] patients: maintain an oxygen saturation between 88% and 92% | ||
Line 70: | Line 71: | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |,|-|-|^|.| | }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |,|-|-|^|.| | }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | D01 | | D02 | | D03 | |D01=<div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Proceed to [[angiography|<span style="color:white;">angiography </span>]]'''<br></div> | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | D01 | | D02 | | D03 | |D01=<div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Proceed to [[angiography|<span style="color:white;">angiography </span>]]'''<br></div> | ||
| D02= <div style="float: left; text-align: center; width: 20em; padding:1em;"> ''' | | D02= <div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Intermediate or high risk''' <br> '''Initial invasive strategy''' </div>| D03= <div style="float: left; text-align: center; width: 20em; padding:1em;"> '''Low risk''' <br> '''Initial conservative strategy''' </div>}} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |!| | | |!| | }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |!| | | |!| | }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | E01 | | E02 | | E03 |E01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | E01 | | E02 | | E03 |E01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> | ||
Line 104: | Line 105: | ||
::❑ Additional bolus of 0.3 mg/kg if needed | ::❑ Additional bolus of 0.3 mg/kg if needed | ||
::❑ Decrease infusion to 1 mg/kg/h when [[creatinine|<span style="color:white;">creatinine</span>]] clearance <30 mL/min | ::❑ Decrease infusion to 1 mg/kg/h when [[creatinine|<span style="color:white;">creatinine</span>]] clearance <30 mL/min | ||
</div>| | </div>|E02=<div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Administer ONE of the following antiplatelet agents either before OR during the time of PCI:'''<br> | ||
'''Before [[PCI|<span style="color:white;">PCI </span>]]'''<br> | '''Before [[PCI|<span style="color:white;">PCI </span>]]'''<br> | ||
❑ [[P2Y12|<span style="color:white;">P2Y12 </span>]] receptor inhibitors <br> | ❑ [[P2Y12|<span style="color:white;">P2Y12 </span>]] receptor inhibitors <br> | ||
:❑ [[Clopidogrel|<span style="color:white;">Clopidogrel </span>]] (600 mg), | :❑ [[Clopidogrel|<span style="color:white;">Clopidogrel </span>]] (600 mg) (I-B), '''''OR'''''<br> | ||
:❑ [[Ticagrelor|<span style="color:white;">Ticagrelor </span>]](180 mg) | :❑ [[Ticagrelor|<span style="color:white;">Ticagrelor </span>]](180 mg) (I-B)<br> | ||
❑ IV [[GP IIb/IIIa|<span style="color:white;">GP IIb/IIIa </span>]] inhibitors <br> | '''''OR'''''<br> | ||
❑ IV [[GP IIb/IIIa|<span style="color:white;">GP IIb/IIIa </span>]] inhibitors (I-A)<br> | |||
:❑ [[Eptifibatide|<span style="color:white;">Eptifibatide </span>]]<br> | :❑ [[Eptifibatide|<span style="color:white;">Eptifibatide </span>]]<br> | ||
::❑ Loading dose 180 mcg/kg IV bolus followed by another bolus after 10 minutes<br> | ::❑ Loading dose 180 mcg/kg IV bolus followed by another bolus after 10 minutes<br> | ||
::❑ Maintenance dose 2 mcg/kg/min, | ::❑ Maintenance dose 2 mcg/kg/min, '''''OR''''' <br> | ||
:❑ [[Tirofiban|<span style="color:white;">Tirofiban </span>]]<br> | :❑ [[Tirofiban|<span style="color:white;">Tirofiban </span>]]<br> | ||
::❑ Loading dose 25 mcg/kg<br> | ::❑ Loading dose 25 mcg/kg<br> | ||
::❑ Maintenance dose 0.15 mcg/kg/min<br> | ::❑ Maintenance dose 0.15 mcg/kg/min<br> | ||
<br>'''''OR'''''<br><br> | |||
'''At the time of [[PCI|<span style="color:white;">PCI </span>]]'''<br> | '''At the time of [[PCI|<span style="color:white;">PCI </span>]]'''<br> | ||
❑ [[P2Y12|<span style="color:white;">P2Y12 </span>]] receptor inhibitors <br> | ❑ [[P2Y12|<span style="color:white;">P2Y12 </span>]] receptor inhibitors <br> | ||
:❑ [[Clopidogrel|<span style="color:white;">Clopidogrel </span>]] (600 mg), | :❑ [[Clopidogrel|<span style="color:white;">Clopidogrel </span>]] (600 mg) (I-A), '''''OR'''''<br> | ||
:❑ [[Ticagrelor|<span style="color:white;">Ticagrelor </span>]] (180 mg), | :❑ [[Ticagrelor|<span style="color:white;">Ticagrelor </span>]] (180 mg) (I-B), '''''OR''''' <br> | ||
:❑ Prasugrel (60 mg)<br> | :❑ Prasugrel (60 mg) (I-B)<br> | ||
❑ IV [[GP IIb/IIIa|<span style="color:white;">GP IIb/IIIa </span>]] inhibitors <br> | '''''OR'''''<br> | ||
❑ IV [[GP IIb/IIIa|<span style="color:white;">GP IIb/IIIa </span>]] inhibitors (I-A)<br> | |||
:❑ [[Eptifibatide|<span style="color:white;">Eptifibatide </span>]]<br> | :❑ [[Eptifibatide|<span style="color:white;">Eptifibatide </span>]]<br> | ||
::❑ Loading dose 180 mcg/kg IV bolus followed by another bolus after 10 minutes<br> | ::❑ Loading dose 180 mcg/kg IV bolus followed by another bolus after 10 minutes<br> | ||
::❑ Maintenance dose 2 mcg/kg/min, | ::❑ Maintenance dose 2 mcg/kg/min, '''''OR''''' <br> | ||
:❑ [[Tirofiban|<span style="color:white;">Tirofiban</span>]] <br> | :❑ [[Tirofiban|<span style="color:white;">Tirofiban</span>]] <br> | ||
::❑ Loading dose 25 mcg/kg<br> | ::❑ Loading dose 25 mcg/kg<br> | ||
::❑ Maintenance dose 0.15 mcg/kg/min </div>}} | ::❑ Maintenance dose 0.15 mcg/kg/min </div> | ||
|E03=<div style="float: left; text-align: left; width: 20em; padding:1em;"> '''Administer ONE of the following antiplatelet agents:'''<br> | |||
❑ [[Clopidogrel|<span style="color:white;">Clopidogrel </span>]] (I-B)<br> | |||
:❑ Loading dose (300 mg)<br> | |||
:❑ Maintenance dose for up to 12 months (75 mg)<br> | |||
❑ [[Ticagrelor|<span style="color:white;">Ticagrelor </span>]] (I-B) | |||
:❑ Loading dose (180 mg)<br> | |||
:❑ Maintenance dose for up to 12 months (90 mg twice daily)</div>}} | |||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |!| | | |!| | }} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | |!| | | |!| | | |!| | }} | ||
{{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | F01 | | F02 | | F03 | |F01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> '''Consider urgent [[CABG|<span style="color:white;">CABG</span>]] if the coronary anatomy is not amenable to PCI and one of the following:'''<ref name="www.ncbi.nlm.nih.gov">{{Cite web | last = | first = | title = ACC/AHA 2004 guideline update for coronary arter... [Circulation. 2004] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed?term=15466654 | publisher = | date = | accessdate = }}</ref> <br> ❑ Patients with left main or left main equivalent disease <br> ❑ Patients with three or two vessel disease involving the left anterior descending artery with left ventricular dysfunction <br> ❑ Diabetic patients </div>|F02=<div style="float: left; text-align: left; width: 25em; padding:1em;"> ❑ Perform an [[angiography|<span style="color:white;">angiography</span>]] </div>|F03={{fontcolor|#000000|'''[[Unstable angina/ NSTEMI resident survival guide#Complete Diagnostic Approach|Continue with the complete diagnostic approach below]]''' }}|boxstyle_F03= background-color: #FFFFFF}} | {{familytree |boxstyle=background: #FA8072; color: #F8F8FF; | F01 | | F02 | | F03 | |F01=<div style="float: left; text-align: left; width: 25em; padding:1em;"> '''Consider urgent [[CABG|<span style="color:white;">CABG</span>]] if the coronary anatomy is not amenable to PCI and one of the following:'''<ref name="www.ncbi.nlm.nih.gov">{{Cite web | last = | first = | title = ACC/AHA 2004 guideline update for coronary arter... [Circulation. 2004] - PubMed - NCBI | url = http://www.ncbi.nlm.nih.gov/pubmed?term=15466654 | publisher = | date = | accessdate = }}</ref> <br> ❑ Patients with left main or left main equivalent disease <br> ❑ Patients with three or two vessel disease involving the left anterior descending artery with left ventricular dysfunction <br> ❑ Diabetic patients </div>|F02=<div style="float: left; text-align: left; width: 25em; padding:1em;"> ❑ Perform an [[angiography|<span style="color:white;">angiography</span>]] </div>|F03={{fontcolor|#000000|'''[[Unstable angina/ NSTEMI resident survival guide#Complete Diagnostic Approach|Continue with the complete diagnostic approach below]]''' }}|boxstyle_F03= background-color: #FFFFFF}} | ||
{{familytree/end}} | {{familytree/end}} |
Revision as of 02:18, 7 April 2015
FIRE: Focused Initial Rapid Evaluation
A Focused Initial Rapid Evaluation (FIRE) should be performed to identify patients in need of immediate intervention.
Boxes in the red color signify that an urgent management is needed.
Identify cardinal findings of unstable angina/ NSTEMI : ❑ Chest pain or chest discomfort
❑ Characteristic ECG changes consistent with unstable angina/ NSTEMI
| |||||||||||||||||||||||
Rule out life threatening alternative diagnoses: ❑ Aortic dissection (suggestive findings: vomiting, subcutaneous emphysema) | |||||||||||||||||||||||
Begin initial treatment: ❑ Administer aspirin (I-A)
❑ Administer 2-4 L/min oxygen via nasal cannula when saturation <90%
❑ Administer beta-blockers (unless contraindicated) and titrate to the heart rate and blood pressure
❑ Administer sublingual nitroglycerin 0.4 mg every 5 minutes for a total of 3 doses
❑ Administer 80 mg atorvastatin | |||||||||||||||||||||||
Does the patient have any of the following indications that require immediate angiography and revascularization ?
❑ Hemodynamic instability or cardiogenic shock | |||||||||||||||||||||||
YES | NO | ||||||||||||||||||||||
Does the patient have negative ECG findings AND negative biomarkers? | |||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||
Repeat ECG and biomarkers within next 6 hours and 12 hours | |||||||||||||||||||||||
ECG and biomarkers are both negative | At least one (ECG or biomarkers) is positive | ||||||||||||||||||||||
Calculate the risk of future adverse clinical outcomes: ❑ Thrombolysis in Myocardial Infarction (TIMI) risk score, OR ❑ GRACE score | |||||||||||||||||||||||
Proceed to angiography | Intermediate or high risk Initial invasive strategy | Low risk Initial conservative strategy | |||||||||||||||||||||
Administer ONE of the following antiplatelet agents (before or at the time of PCI):
Prasugrel is contraindicated in case of prior history of strokes or TIAs, active pathological bleeding, age ≥75 years, when urgent coronary artery bypass graft surgery (CABG) is likely, body weight <60 kg, propensity to bleed, concomitant use of medications that increase the risk of bleeding
Administer ONE of the following anticoagulant therapy:
| Administer ONE of the following antiplatelet agents either before OR during the time of PCI: Before PCI
OR
OR
| Administer ONE of the following antiplatelet agents: ❑ Clopidogrel (I-B)
❑ Ticagrelor (I-B)
| |||||||||||||||||||||
❑ Perform an angiography | Continue with the complete diagnostic approach below | ||||||||||||||||||||||